<DOC>
	<DOCNO>NCT01746173</DOCNO>
	<brief_summary>The current standard care frontline treatment peripheral T-cell lymphoma ( PTCL ) induction chemotherapy follow autologous stem cell transplantation ( ASCT ) . However , many patient unable get ASCT relapse ASCT , poor prognosis . Recently , novel ASCT condition regimen gemcitabine , busulfan melphalan ( Gem/Bu/Mel ) report lead favorable outcome disease . We therefore design frontline regimen CHOEP induction follow Gem/Bu/Mel ASCT , report result phase 2 study regimen patient PTCL .</brief_summary>
	<brief_title>CHOEP + High Dose Therapy + Auto SCT T-Cell Lymphoma</brief_title>
	<detailed_description>Objectives : Primary - To estimate proportion patient alive progression-free 24 month begin induction therapy Secondary - To estimate response rate ( complete remission ( CR ) partial remission ( PR ) ) CHOEP x 6 Gem/Bu/Mel ASCT - To estimate overall survival ( OS ) , progression-free survival ( PFS ) , cumulative incidence relapse ( CIR ) , non-relapse mortality ( NRM ) - To estimate toxicity ( grade 3 ) - To estimate rate successful stem cell mobilization CHOEP respond patient - To estimate proportion patient successfully complete entire treatment regimen - To estimate time engraftment neutrophil platelet engraftment ASCT - To determine whether tumor DNA detect peripheral blood patient therapy - To evaluate change prognostic relevance detectable tumor DNA peripheral blood induction chemotherapy ( CHOEP ) Gem/Bu/Mel ASCT</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Diagnosis TCell lymphoma mandatory pathologic review Brigham Women 's Hospital Massachusetts General Hospital Measurable disease Candidate Autologous Stem Cell Transplant Prior antilymphoma chemotherapy ( except steroids/radiotherapy urgent palliation , one prior cycle CHOP 2 prior cycle CHOEP ) Pregnant breastfeed Alkpositive ACL Significant neuropathy preclude vincristine administration Known hypersensitivity agent use treatment Uncontrolled intercurrent illness Receiving investigational agent History different malignancy except disease free least 5 year cervical cancer situ basal cell/squamous cell carcinoma skin HIV positive antiretroviral therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>T Cell lymphoma</keyword>
</DOC>